Press-release for stocks related to pharm-country

Prices are updated after-hours

tags : Pharm-country

save search

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Published: 2023-02-08 (Crawled : 23:00) - biospace.com/
CARA S | $11.67 -2.26% -2.31% 170K

Health Technology

| -1.68% | O: 1.01% H: 1.92% C: -2.67%
treatment pruritus for trial therapeutics results

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
Published: 2023-02-08 (Crawled : 17:00) - biospace.com/
OVID | $2.4 -5.14% -7.2% 110K

Health Technology

| 0.42% | O: 4.6% H: 0.8% C: -4.0%
therapeutics

BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BTAI | $33.24 8.31% 7.62% 730K

Health Technology

| 10.73% | O: 5.06% H: 6.5% C: 5.39%
bxcl701 day rare for therapeutics cancer

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BDX S | $250.23 -1.17% 0.0% 1.1M

Health Technology

| 1.06% | O: 1.06% H: 0.0% C: 0.0%
covid-19 fda for test rsv authorization influenza

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BRTX | $3.0 -0.35% 1.94% 52K

Professional, Scientific, and T...

| -2.6% | O: -1.3% H: 7.89% C: -1.32%
thermostem patent for program

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
Published: 2023-02-08 (Crawled : 13:00) - biospace.com/
IPSC A | $4.65 -2.31% -2.15% 110K

Professional, Scientific, and T...

| 0.22% | O: 4.53% H: 1.03% C: -4.12%
cnty-101 lymphomas cd19 trial therapeutics positive

Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
OTLK | $1.27 0.0% 470K

Health Technology

| 7.63% | O: 8.9% H: 0.0% C: 0.0%
therapeutics biopharma global

BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
BSGM P 349323 | $1.17 2.63% 2.56% 260K

Health Technology

| 0.0% | O: 1.71% H: 0.0% C: 0.0%
qorvo

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
MRNS S | $7.25 8.05% 7.32% 860K

Health Technology

| 10.35% | O: -1.52% H: 0.0% C: 0.0%
pharmaceuticals

Hyperfine Swoop® Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract InclusionsResearch highlights the significance and clinical relevance of portable MRI technology
Published: 2023-02-06 (Crawled : 01:00) - biospace.com/
HYPR | $1.22 8.93% 7.44% 280K

Manufacturing

| 0.85% | O: 10.26% H: 0.0% C: 0.0%
swoop technology

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
SEEL | $0.8002 -6.95% -7.17% 440K

Health Technology

| -7.79% | O: -4.36% H: 6.01% C: 6.01%
sls-002 therapeutics study

Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
JNJ | $163.61 0.13% 0.15% 4.7M

Health Technology

| -1.59% | O: -0.75% H: 0.0% C: 0.0%
risk disease for topline positive results

ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
PRPH | $8.14 -0.85% -1.23% 40K

Health Technology

| 0.37% | O: 3.82% H: 0.0% C: -6.29%
program update cancer

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
BMY S | $73.65 -1.17% 0.03% 7.9M

Health Technology

| 2.19% | O: 0.65% H: 0.0% C: 0.0%
conference

Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference - February 3, 2023
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
TNXP | $1.23 4.24% 2.48% 4M

Health Technology

| 6.03% | O: 6.9% H: 0.0% C: 0.0%
pharmaceuticals ceo conference

PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
PXMD | $3.3 -8.84% -10.03% 600K

Health Technology

| 6.45% | O: 17.42% H: 0.0% C: 0.0%
growth

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRK S | $106.64 0.91% 0.16% 6.7M

Health Technology

| 3.07% | O: -0.31% H: 0.0% C: 0.0%
keytruda for plus therapy

Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend
Published: 2023-02-03 (Crawled : 12:20) - biospace.com/
CI G | $290.2 0.42% 0.0% 2M

Health Services

| -6.39% | O: -1.82% H: 0.0% C: 0.0%
dividend year

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
YMAB | $4.28 -4.89% -5.14% 220K

Health Technology

| -3.3% | O: 2.64% H: 4.29% C: 3.43%
for agreement

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
MRK S | $106.64 0.91% 0.16% 6.7M

Health Technology